About: Simtuzumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.

Property	Value
dbo:abstract	Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. (en)
dbo:casNumber	1318075-13-6
dbo:fdaUniiCode	11Z5AIU653
dbo:wikiPageID	38271060 (xsd:integer)
dbo:wikiPageLength	2152 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1002216099 (xsd:integer)
dbo:wikiPageWikiLink	dbr:LOXL2 dbr:International_Nonproprietary_Name dbc:Monoclonal_antibodies dbr:Fibrosis
dbp:atcPrefix	none (en)
dbp:c	6558 (xsd:integer)
dbp:casNumber	1318075 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	10134 (xsd:integer)
dbp:iupharLigand	8412 (xsd:integer)
dbp:mabType	mab (en)
dbp:n	1736 (xsd:integer)
dbp:o	2037 (xsd:integer)
dbp:s	50 (xsd:integer)
dbp:source	zu (en)
dbp:target	dbr:LOXL2
dbp:type	mab (en)
dbp:unii	11 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Fdacite dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dct:subject	dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. (en)
rdfs:label	Simtuzumab (en)
owl:sameAs	freebase:Simtuzumab wikidata:Simtuzumab https://global.dbpedia.org/id/4uSPC yago-res:Simtuzumab
prov:wasDerivedFrom	wikipedia-en:Simtuzumab?oldid=1002216099&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Simtuzumab
is dbo:wikiPageRedirects of	dbr:GS-6624
is dbo:wikiPageWikiLink of	dbr:LOXL2 dbr:Cholestasis dbr:Idiopathic_pulmonary_fibrosis dbr:Primary_sclerosing_cholangitis dbr:List_of_therapeutic_monoclonal_antibodies dbr:GS-6624
is foaf:primaryTopic of	wikipedia-en:Simtuzumab

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License